These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21982514)

  • 81. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.
    Podolin PL; Callahan JF; Bolognese BJ; Li YH; Carlson K; Davis TG; Mellor GW; Evans C; Roshak AK
    J Pharmacol Exp Ther; 2005 Jan; 312(1):373-81. PubMed ID: 15316093
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion.
    Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Centorrino T; Siriwardena AK; Cuzzocrea S
    Shock; 2007 May; 27(5):542-51. PubMed ID: 17438460
    [TBL] [Abstract][Full Text] [Related]  

  • 84. (E)-3-(3,4-Dimethoxyphenyl)-1-(5-hydroxy-2,2-dimethyl-2H-chromen-6-yl)prop-2-en-1-one ameliorates the collagen-arthritis via blocking ERK/JNK and NF-κB signaling pathway.
    Li X; Peng F; Xie C; Wu W; Han X; Chen L
    Int Immunopharmacol; 2013 Dec; 17(4):1125-33. PubMed ID: 24135236
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis.
    Lon HK; Liu D; Zhang Q; DuBois DC; Almon RR; Jusko WJ
    Pharm Res; 2011 Jul; 28(7):1622-30. PubMed ID: 21360252
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.
    Bendele AM; Chlipala ES; Scherrer J; Frazier J; Sennello G; Rich WJ; Edwards CK
    Arthritis Rheum; 2000 Dec; 43(12):2648-59. PubMed ID: 11145022
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Interleukin-10 inhibition of the progression of established collagen-induced arthritis.
    Walmsley M; Katsikis PD; Abney E; Parry S; Williams RO; Maini RN; Feldmann M
    Arthritis Rheum; 1996 Mar; 39(3):495-503. PubMed ID: 8607899
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
    Fabre S; Dupuy AM; Dossat N; Guisset C; Cohen JD; Cristol JP; Daures JP; Jorgensen C
    Clin Exp Immunol; 2008 Aug; 153(2):188-95. PubMed ID: 18549443
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
    Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
    Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
    J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Gene expression profiling and functional analysis of angiogenic markers in murine collagen-induced arthritis.
    Raatz Y; Ibrahim S; Feldmann M; Paleolog EM
    Arthritis Res Ther; 2012 Jul; 14(4):R169. PubMed ID: 22817681
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse.
    Kim H; Bang J; Chang HW; Kim JY; Park KU; Kim SH; Lee KJ; Cho CH; Hwang I; Park SD; Ha E; Jung SW
    Eur J Pharmacol; 2012 Mar; 678(1-3):55-60. PubMed ID: 22209881
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis.
    Juarranz Y; Abad C; Martinez C; Arranz A; Gutierrez-Cañas I; Rosignoli F; Gomariz RP; Leceta J
    Arthritis Res Ther; 2005; 7(5):R1034-45. PubMed ID: 16207319
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures.
    Schmidt EM; Davies M; Mistry P; Green P; Giddins G; Feldmann M; Stoop AA; Brennan FM
    Arthritis Rheum; 2013 Sep; 65(9):2262-73. PubMed ID: 23784528
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Etanercept Immunex.
    Yung RL
    Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A novel single domain bispecific antibody targeting VEGF and TNF-α ameliorates rheumatoid arthritis.
    Zhang N; Zheng N; Luo D; Lin J; Lin D; Lu Y; Lai W; Bian Y; Wang H; Ye J; Yang J; Liu J; Que W; Chen X
    Int Immunopharmacol; 2024 Jan; 126():111240. PubMed ID: 37992444
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo.
    Amat M; Benjamim CF; Williams LM; Prats N; Terricabras E; Beleta J; Kunkel SL; Godessart N
    Br J Pharmacol; 2006 Nov; 149(6):666-75. PubMed ID: 17016504
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
    Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
    J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Collagen II antibody-induced arthritis in Tg1278TNFko mice: optimization of a novel model to assess treatments targeting human TNFα in rheumatoid arthritis.
    Moore AR; Allden S; Bourne T; Denis MC; Kranidioti K; Okoye R; Sotsios Y; Stencel Z; Vugler A; Watt G; Shaw S
    J Transl Med; 2014 Oct; 12():285. PubMed ID: 25344414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.